NOTES

A New Trichostatin Derivative, Trichostatin RK, from *Streptomyces* sp. RK98-A74

MASASHI UEKI^a, TAKAYUKI TERUYA^{a,b}, LIN NIE^a, Ron Usami^b, Minoru Yoshida^c and Hiroyuki Osada^a

^a Antibiotics Laboratory, RIKEN Institute, Hirosawa 2-1, Wako-shi, Saitama 351-0198, Japan
^b Faculty of Engineering, Toyo University, Kujirai 2100, Kawagoe-shi, Saitama 350-8585, Japan
^c Graduate School of Agriculture and Life Science, The University of Tokyo, Yayoi 1-1-1, Bunkyo-ku, Tokyo 113-8657, Japan

(Received for publication June 18, 2001)

The tumor suppressor gene, p53, is found to be mutated or deleted in more than 50% of human tumor cells. Dysfunction of p53 by mutation or deletion resulted in down-regulation of p53-inducible genes, such as CDK (cyclin dependent kinase) inhibitor $p21^{WAF1}$. Natural products, which activate the p21 promoter and then upregulate its expression, can be cancer chemotherapeutic drugs.

In the course of a screening program of the p21 promoter¹⁾, we found that three actinomycete strains produced the compound(s) enhancing the luciferase activity of H1299/tsp53-Luc cells. All of the three strains produced trichostatin derivatives, and one strain, RK98-A74, was found to produce a new trichostatin derivative, trichostatin RK.

The producing organism, strain RK98-A74, was isolated from a soil sample collected at Okutama in Tokyo Metropolis. The strain was cultured on an ISP-2 agar plate for $14\sim20$ days at 28°C, and then its morphological characteristics were observed. RK98-A74 grew very well, and formed abundant aerial mycelia. The mature aerial mycelia corresponded to the gray color series. The reverse side of the colony was white to light gray. Substrate and aerial mycelia of strain RK98-A74 were well-branched and not fragmented. Substrate RK98-A74 formed spiral chain of spores with $15\sim20$ per chain on the aerial mycelium. The spores were spherical or egg-shaped, $0.5 \sim 0.6 \times 0.5 \sim 0.8 \,\mu$ m in size with a smooth surface (Fig. 1). Sclerotia, sporangia, and zoospores were not observed. Analysis of the whole cell hydrolysates showed the presence of L,L-diaminopimelic acid, so the cell wall of this strain is classified as type I. Based on these and other characteristics, the strain RK98-A74 was deemed to belong to genus *Streptomyces*, and named *Streptomyces* sp. RK98-A74.

Strain RK98-A74 was cultivated for 4 days at 28°C with shaking in the producing medium (containing 1.0% glucose, 0.5% yeast extract, 0.5% malt extract, adjusted at pH 7.0). Three liters of the culture broth were extracted with the same volume of acetone, and filtered. The filtrate was concentrated in vacuo to give an aqueous solution, which was extracted with 3 liters of EtOAc. The organic layer was concentrated in vacuo to yield an oily material, which was dissolved in a small volume of CHCl₃ and applied to a silica gel column (Silica gel 60, Merck). Absorbed material was eluted with CHCl₃ and MeOH. Fractions (CHCl₃: MeOH=90:10) enhancing luciferase activity were collected and concentrated in vacuo. The crude mixture was dissolved in a small amount of MeOH, applied on a preparative HPLC (Pegasil ODS i.d. 20×250 mm, Senshu Science Co.) and developed with 70~80% aqueous MeOH. Three fractions, which UV

Fig. 1. *Streptomyces* sp. RK98-A74. Bar presents 2.0 µm.



Fig. 2. Structures of trichostatins.



Trichostatin A (TSA); R = -NHOH Trichostatic acid (TSacid); R = -OH Trichostatin RK (TSRK); R = -NHCH₃ FL657C; R = -NH₂ Trichostatin C (TSC); R = -NHO- β -D-Glc Monomethyl TSA; R = -NCH₃OH Dimethyl TSA; R = -NCH₃OCH₃

spectra were similar to each other; compounds 74-1 (1.0 mg), 74-2 (0.6 mg) and 74-3 (1.3 mg), were obtained. Based on instrumental analyses, compounds 74-1 and 74-3 were identified to be trichostatin A $(TSA)^{21}$ and trichostatic acid $(TSacid)^{21}$, respectively (Fig. 2). Compound 74-2, namely trichostatin RK (TSRK), was deemed to be a new trichostatin derivative, further analysis for structure determination was carried out.

The UV spectrum of TSRK in MeOH possessed λ_{max} at 265 and 350 nm, which was identical with TSA. The base peak at m/z 301 (M+H⁺) and fragment ions at m/z 148 (C₉H₁₀NO⁺; corresponding to N-dimethyl-paminobenzylacylium ion), 177 and 270 were observed in the FAB-MS spectrum of TSRK (Fig. 3), indicating that the structure of TSRK was very close to that of TSA. The ¹H and ¹³C NMR spectral data of TSRK shown in Table 1 are very similar to that of TSA as described previously³, but additional signals of a methyl carbon at 26.3 ppm and a methyl proton at 2.88 ppm were observed in the ¹³C and ¹H NMR spectral data of TSRK. The structure of TSRK was deduced by ¹H-¹H COSY, HMQC and HMBC experiments. Figure 3 shows ¹H-¹H couplings detected by COSY, and long-range couplings observed in the HMBC experiment. The correlation from the methyl protons at 2.88 ppm to a carbon at 167.1 ppm in the HMBC spectrum was observed. Moreover, a specific fragment suggesting an aminomethyl carbonyl ion was observed at m/z 58 in the FAB-MS spectrum of TSRK. These results suggest that the additional methyl group of TSRK was substituted for a hydroxyl group in the hydroxamic acid moiety of TSA. Accordingly, the structure of TSRK was determined as

Table	1.	'H and	"C NM	IR spectra	al data	of ISR	ĸ
in C	DCI	2.					
		5					

1130 30 00

C-No.	$\delta_{\rm C}$	δ_{H}	(multiplicity, J=Hz)
1-NCH ₃	26.3	2.88	(d, 5.2, 3H)
1	167.1		
2	119.1	5.78	(d, 15.5)
3	144.7	7.16	(d, 15.5)
4	132.3		
4-CH ₃	12.6	1.89	(s, 3H)
5	140.0	5.97	(d, 9.8)
6	40.8	4.35	(dq, 9.4, 6.8)
6-CH3	17.6	1.30	(d, 6.6, 3H)
7	198.6		
8	123.9		
9, 13	130.5	7.84	(d, 7.2, 2H)
10, 12	110.6	6.63	(d, 7.2, 2H)
11	153.3		
11-N(CH ₃) ₂	39.9	3.05	(s, 6H)





Bold bars and arrows present ¹H-¹H COSY and HMBC correlations, respectively. Dashed lines with arrowheads indicate common fragments observed in FAB-MS spectra of trichostatin derivatives. Plain line with arrowhead shows specific fragment observed in FAB-MS spectrum of TSRK.

shown in Fig. 3.

The inducible activities of luciferase expression in H1299/tsp53-Luc cells by the trichostatin derivatives (Fig. 4) were measured the same as described in the accompanying report¹⁾. TSA, TSacid and TSRK were

Fig. 4. Luciferase activity induced by trichostatin derivatives.



Symbols indicate the following; \bigcirc : trichostatin A, \blacksquare : trichostatic acid, \spadesuit : trichostatin RK, \triangle : FL657C, \Box : trichostatin C, \blacktriangle : monomethyl trichostatin A, ∇ : dimethyl trichostatin A.

isolated from the culture broth of the strain RK98-A74. Trichostatin C (TSC)²⁾ and FL657C⁴⁾ were isolated from another actinomycete strain RK98-A34, and monomethyl and dimethyl TSA were chemically synthesized. As shown in Fig. 4, TSA induced the luciferase activity over 4-fold at 50 ng/ml, TSacid and FL657C had the same effect at $2 \sim 3 \,\mu$ g/ml. However, TSRK, TSC, monomethyl and dimethyl TSA hardly induced activity. It is known that p21 promoter is activated by TSA due to its inhibitory activity against histone deacetylase (HDAC)⁵⁾. A structure-activity relationship study of HDAC and TSA has revealed that the hydroxamic acid moiety of TSA is important for high affinity with the active-site cavity bearing the zinc ion in HDAC⁶⁾. TSacid and FL657C reduced the inhibitory activity because of the loss of the hydroxamic acid moiety. It was reported that TSacid has no effect on cell differentiation, cell cycle⁷⁾ and in vitro HDAC activity⁸⁾. However, TSacid induced the luciferase activity in H1299/tsp53-Luc cells in our assay system, which involved its HDAC inhibition and other unknown mechanism. Induction of luciferase activity by TSRK, TSC, monomethyl and dimethyl TSA was not observed, because their bulky groups (methyl, dimethyl and glucosyl group) may obstruct binding to the active-site pocket of HDAC. The relationship between the trichostatin derivatives and luciferase activity is apparently consistent with the mode of action of trichostatin on HDAC inhibition

Acknowledgement

We are grateful to Prof. K. MORI, The Tokyo University of Science, for supplying synthetic trichostatin derivatives, monomethyl and dimethyl TSA. This work was supported by a Grant for Multibioprobe (RIKEN) and by a Grant from the Ministry of Education, Science, Sports and Culture, Japan.

References

- LIN, N.; M. UEKI, H. KAKEYA & H. OSADA: A facile and effective screening method for p21^{WAF1} promoter activator from microbial metabolites with reporter gene assay. J. Antibiotics 54: 783~788, 2001
- TSUJI, N.; M. KOBAYASHI, K. NAGASHIMA, Y. WAKISAKA & K. KOIZUMI: A new antifungal antibiotic, trichostatin. J. Antibiotics 29: 1~6, 1976
- MORI, K. & K. KOSEKI: Synthesis of trichostatin A, a potent differentiation inducer of Friend leukemic cells, and its antipode. Tetrahedron 44: 6013~6020, 1988
- ISHIHARA, M.: K. MORIOKA, H. SHIBAI & Y. KOMODA. Japan Kokai Tokkyo Koho JP01-29926, 1989
- KIM, Y.-B.; S.-W. KI, M. YOSHIDA & S. HORINOUCHI: Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J. Antibiotics 53: 1191~1200, 2000
- 6) FURUMAI, R.; Y. KOMATSU, N. NISHINO, S. KHOCHBIN, M. YOSHIDA & S. HORINOUCHI: Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. U.S.A. 98: 87~92, 2001
- 7) YOSHIDA, M.; Y. HOSHIKAWA, K. KOSEKI, K. MORI & T. BEPPU: Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. J. Antibiotics 43: 1101~1106, 1990
- YOSHIDA, M.; M, KIJIMA, M. AKITA & T. BEPPU: Potent and specific inhibition of mammalian histone deacetylase both *in vivo* and *in vitro* by trichostatin A. J. Biol. Chem. 265: 17174~17179, 1990